Doesn't Really Mean "Losing" $$ (grin)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RBMS getting some momentum, already up 5% on it
RMBS--insider purchased 20k shares, do your own research. Subscribers seen that this came in late after close on friday, so there was a lot of time for research over the weekend.
From what? Being a douche?
lmfao
FOR ALL FOLLOWERS THAT HAVE PURCHASED THE REAL TIME MATRIX PLAYS:
THIS IS A CHEAT SHEET HOW TO KNOW WHICH PLAYS I LOOK AT WHEN I AM GETTING THE REAL TIME PLAYS. I HAVE EMAILED A FEW PEEPS THIS, BUT I WILL STICKY THIS AND MAYBE ADD SOME MORE POINTERS WHEN I HAVE TIME:
Here are a few things that we look for after it comes through the micromatrix:
1: Was it a recent buy? (sometimes insider buys record with the sec many weeks even months later, dont know why but sometimes this is the case), never buy these
2: Was the buy a round number (if not, it might be a stock offering purchase or something, then do more research), but like if the CEO buys 50,000 shares, that is good, etc.
3: Don't really like bank or financial stocks, if everything else is perfect, then we may play them
4: We like Bio's / Tech's / Oil stocks preferrably
5: CEO / CFO / COO buys are the best historically
6: Often times there will be multiple buys over a span of time on the same stock, DO NOT KEEP BUYING IT, PLAY THE FIRST BUY, THEN THAT IS IT (typically, there are always exceptions)
7: Look at volume / short position / where it is historically on the yearly or six month chart, the lower it is on the chart, the more boom potential it has
8: Don't just start buying the plays, look at them for some time, track them, you will now have your own data base, you will soon learn how to overlook the trash, and spot the winners. (of course there are always plays that I don't like that blow up) but we are looking for consistant gains
9: THIS IS A SYSTEM, NOT A GET RICH QUICK SCEME. REMEMBER THIS, PLUG AWAY, BE DICIPLINED, LOOK AT OUR STATS, YOU WILL HAVE LOSERS AND WINNERS, JUST MORE WINNERS OVER TIME!
10: IF ALL THESE THINGS ARE IN LINE, EARLY BIRD GETS THE WORM, YOU WILL BE GETTING THE ALERT REAL TIME, SO CAN'T WAIT TOO LONG, YOU WILL LEARN TO LOOK AT THEM QUICK, AND THE ALERT HAS A LOT OF INFO ALREADY ON IT.
Damn good HOroshi, I just sent you a PM with my personal email
PCO, wow, up over 15% since the call last week
PCO, just hit 10% in a week, that was a nice play, I bailed yesterday for 7%.
Game, did you get the email I sent? Thanks
Jason
Thanks for the kind words. Read the ibox, we posted our plays for two years n have tracked legitimate stats that reflect a 70% win percentage. In the world of stocks that is phenominal. I have made a lot of posts regarding this. We should have our real time calls available to he public in the next few days on scumfish.com.
Pm me if u have specific questions
NFLX, wow.
Insiders that have subscribed to the Micro Matrix, remember, look over the alerts, and make informed decisions. You will see now that you are getting all the live alerts, that there are many more alerts than I post, as I don't have a lot of confidence in them. Remember, CEO buys or COO buys are always perceived as the best. Always look at the date of purchase, as there are times the form 4 records on the SEC website much later than the buy (for many different reasons). if the buy date is dated a little, don't play it.
lol
PCO, closed out just now with a 7.1% gain, not bad on a red week
Excellent mtl, that one was a phenominal play
Send it again, I thought I sent it
Hey bud, will send you a pm
I watch that on my apple tv n lol everytime
Lmfao
I agree, nobody will change until foreign soldiers step foot on our soil, then they will understand the risk of war
PCO--10% owner purchased 2.5 million shares at $1.14. Stock closed at $1.27. Do your own research. This will be one of the last real time plays I post guys, I am just over extended in my business ventures, and don't have a lot of free time for message boards.
insider data provided by www.scumfish.com
Pendrell Corporation, formerly ICO Global Communications (Holdings) Limited, incorporated on March 17, 2000, along with its subsidiaries is a development stage mobile satellite service (MSS) operator. On May 15, 2009, the Company's majority-owned subsidiary, DBSD North America, Inc., along with its subsidiaries (collectively referred to as DBSD) filed voluntary petitions for reorganization under Chapter 11 of Title 11 of the United States Bankruptcy Code (Chapter 11 cases) in the United States Bankruptcy Court for the Southern District of New York (Bankruptcy Court). In June 2011, the Company acquired Ovidian Group. In October 2011, the Company's subsidiary, Pendrell Technologies LLC, acquired 90.1% interest in ContentGuard Holdings, Inc. In November 2011, Technicolor SA sold its 25.7% interest in ContentGuard to Pendrell Technologies LLC, a wholly owned subsidiary of Pendrell Corporation.
Insiders, I wanted to share something interesting. So on 04/04/12, our matrix picked up a nice insider buy on WOLF of 705,000 shares at $5.64, stock was trading at $5.70. I was just to busy to play it, as my real estate company is booming, and I am partners in another technology company. Anyway, the stock blew up, and today there is news why, a buyout. My point is, this is why you have to have the real time feed from scumfish, as there are just a lot of plays that I don't have time to play, and they are good. We will have the link for the public to buy real time microinsider on our scumfish website by the eom.
lolol, nice.... we got our first contract on the new business. web site is up (not finalized, just had to get something up).
lol, just a matter of time before you got muscle cocky, I've been there and done that. remember I am 39, and I get sex whenever I want it by "willing female" participants. Not like you having to fly to florida to get down with nitty, lol
your getting too ripped for him, he likes his men a little more soft, lol
STFU, too bad you can't get your mind ripped too, lol
Hey Insiders, been pretty slow as the market is toppy. As far as the private messages I sent a handfull of peeps, it is comming I promise, just a few more days.
Thanks
Lmfao
That pic is funny, lolol
AAPL
seriously????? your such a dick
LTS more news, lets see how the reaction is. I have a pretty substancial position on this swing, so come on baby!!
Ironridge BioPharma to Invest $500,000 in Pressure BioSciences
8:15a ET April 9, 2012 (GlobeNewswire) Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company") today announced that it has entered into a definitive agreement with Ironridge BioPharma Co. ("Ironridge") to purchase $500,000.00 in shares of Series E Convertible Preferred Stock (the "Preferred Stock") of the Company.
Each share of the 500 shares of Preferred Stock to be sold to Ironridge is convertible into approximately 980 shares of Common Stock, which is determined by dividing the stated value of the Series E Preferred Stock of $1,000 by a fixed conversion price of $1.02 per share. The conversion price is not subject to any price anti-dilution protection. Ironridge will receive no warrants. There are few restrictive covenants and no amortization provisions in the transaction. The Preferred Stock will accrue dividends at 10.5% per annum, subject to a credit risk and make-whole adjustment, and is payable in cash or shares of registered Common Stock at the discretion of PBI. Under certain conditions and subject to certain limitations, the Company may require Ironridge to convert their Preferred Stock into Common Stock. The transaction is subject to customary closing conditions.
In connection with the transaction, Ironridge represented that it has never shorted the Company's stock, does not hold any short position in the Company's stock, and will not engage in or effect, directly or indirectly, any short sale for at least one year.
"We are very impressed with PBI's patented and enabling Pressure Cycling Technology ("PCT") Platform, their existing customer base, their accomplishments over the past year, and their hard-working and talented staff," commented Ironridge Managing Director, Brendan O'Neil. "We are excited about this financing transaction, and hope this is the beginning of a long and mutually beneficial relationship."
Richard T. Schumacher, President and CEO of PBI, said: "We appreciate Ironridge's life science focus, and believe they are a great capital partner for us as we seek to fill a large and growing need in the sample preparation marketplace in the life sciences industry."
Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE AMEX:LTS), acted as the exclusive placement agent for the transaction.
The offering is expected to close on or about April 11, 2012, subject to the satisfaction of customary closing conditions.
The securities described above are being offered pursuant to a shelf registration statement, as amended (File No. 333-176828), which was declared effective by the United States Securities and Exchange Commission ("SEC") on September 26, 2011. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. When filed with the SEC, copies of the prospectus supplement and the accompanying base prospectus relating to this offering may be obtained at the SEC's website at http://www.sec.gov.
About Ironridge BioPharma Co.
Ironridge BioPharma Co., a division of Ironridge Global IV, Ltd., specializes in equity investments in the life sciences sector, including companies involved in biotechnology, pharmaceuticals, medical devices and enabling technologies. Ironridge is a long-only institutional investor that entered into more than twenty equity financing transactions last year, ranging from a quarter million to ten million dollars each. Ironridge seeks to be a long-term financial partner, assisting public companies in financing operations and expansion by supplying innovative funding solutions and flexible capital. The firm seeks to unlock the full potential of cash-constrained businesses, propelling higher growth and more profitable enterprises. For more information on Ironridge, please visit www.IronridgeGlobal.com.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCQB:PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology ("PCT"). PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.
Forward Looking Statements
Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements include statements regarding the purchase by Ironridge of $500,000 of the Company's Series E Convertible Preferred Stock, the relationship between the Company and Ironridge, and the estimated size of the life sciences sample preparation market. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: possible difficulties or delays in the implementation of the Company's strategies that may adversely affect the Company's continued and expanded commercialization of its PCT-based product line; changes in customer's needs and technological innovations; the Company's sales force and distribution network may not be successful in selling the Company's PCT product line because scientists may not perceive the advantages of PCT over other sample preparation methods; and the Company may not be successful in raising additional capital necessary to fund the Company's operations. Given the uncertainty in the capital markets and the current status of the Company's product development and commercialization activities, there can be no assurance that the Company will secure the additional capital necessary to fund its operations beyond May 2012 on acceptable terms, if at all. Additional risks and uncertainties that could cause actual results to differ materially from those indicated by these forward-looking statements are discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2011, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
For more information about PBI and this press release, please click on the following links: http://www.pressurebiosciences.com
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Pressure BioSciences, Inc.
CONTACT: Richard T. Schumacher, President & CEO
Pressure BioSciences, Inc.
Brendan O'Neil, Managing Director
Ironridge BioPharma Co.
LTS news, ug.
DARA BioSciences To Raise $10.1 M In Public Offering
Last update: 4/9/2012 9:05:13 AM
(MORE TO FOLLOW) Dow Jones Newswires (212-416-2800)
April 09, 2012 09:05 ET (13:05 GMT)
I know, I am still holding on hope with this play, but very close to exiting...
lol
Post what?
your such a fag, they said my micro stats were spam on this board wtf. Check your pm douchette
ya, I bought it, then set a sell at 1.63, and looked at close, and I was out, those are my favorite, lol
This was a pretty nice swing trade on KERX
Entered at 3.50 pm at 1.51, sold at 3.59 at 1.631, 8% in 9 min and 30 sec, I wish they were all this easy
KERX--CEO purchased 71.4k shares at 1.38. Stock is trading at 1.49. Do your own research, large short position.
insider data provided by www.scumfish.com
Keryx Biopharmaceuticals, Inc. (Keryx) is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and renal disease. The Company is developing KRX-0401 (perifosine), an oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the Jun N-terminal kinases pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is in Phase III clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase I and Phase II clinical development for several other tumor types. The Company is developing Zerenex (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes.